For the adjuvant treatment of patients with HER2-positive early breast cancer, who have residual disease, after pre-operative systemic treatment. KADCYLA should be continued for 14 cycles or until disease progression or unacceptable toxicity. If KADCYLA is discontinued in the event of toxicity, treatment with trastuzumab may be continued to complete one year of HER2-directed therapy.
‡ Patient Advocacy Groups (or individual patients and caregivers
when there is no patient group) and Clinicians who are registered
with pCODR are eligible to provide Input and Feedback.
Deadlines for Input and Feedback are by the end of the pCODR business day
(5P.M. Eastern Time) of the date noted.